Dr. Albiges on the Impact of BMI on Outcomes of Patients With mRCC

Laurence Albiges, MD
Published: Thursday, Feb 26, 2015



Laurence Albiges, MD, visiting scientist, Dana-Farber Cancer Institute, discusses a study that looked at the impact of body mass index (BMI) on outcomes of patients with metastatic renal cell carcinoma (mRCC).

Albiges says obesity and being overweight are established risk factors to develop RCC. Conversely, patients that are overweight typically have smaller tumors and have better outcomes.

This study looked at approximately 4000 patients with mRCC treated with systemic therapy. It was confirmed that patients with high BMI were more likely to have a longer overall survival, longer time to treatment failure, and better tumor shrinkage, compared with patients with low or normal BMI.

<<< View more from the 2015 GU Cancer Symposium



Laurence Albiges, MD, visiting scientist, Dana-Farber Cancer Institute, discusses a study that looked at the impact of body mass index (BMI) on outcomes of patients with metastatic renal cell carcinoma (mRCC).

Albiges says obesity and being overweight are established risk factors to develop RCC. Conversely, patients that are overweight typically have smaller tumors and have better outcomes.

This study looked at approximately 4000 patients with mRCC treated with systemic therapy. It was confirmed that patients with high BMI were more likely to have a longer overall survival, longer time to treatment failure, and better tumor shrinkage, compared with patients with low or normal BMI.

<<< View more from the 2015 GU Cancer Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x